o “Tratar num todo e como um todo: o doente e o seu meio ambiental” entrevista: Santos I, Painetwork, 2013,3:29-32
o “Short form 6D: can measure health in patients with systemic lupus erythematosus?”, Ribeiro C, Santos I, Veiga N, Marques A, Vasconcelos C., Rev Saúde Pública 2014;48(n.esp):141
Bibliografia
1. Dequeker J. Arthritis in Flemish paintings (1400-1700). Br Med J. 1977;1(6070):1203–5.
2. Caughey DE. The arthritis of Constantine IX. Ann Rheum Dis. 1974;33(1):77– 80.
3. Storey GD. Alfred Baring Garrod (1819-1907). Rheumatology (Oxford). 2001;40(10):1189–90.
4. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism
Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315–24.
5. Aletaha D, Neogi T, Silman AJ, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69(9):1580–8. 6. Louveau A, Smirnov I, Keyes TJ, et al. Structural and functional features of
central nervous system lymphatic vessels. Nature. Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.;
2015;523(7560):337–41.
7. Marcus D, Cope D, Deodhar A, et al. Chronic Pain: Atlas of Investigation and Management. 1st ed. Oxford: Clinical Publishing; 2009. 146 p.
8. The Lancet. Patient empowerment—who empowers whom? [Internet]. The Lancet. 2012. p. 1677.
9. Zabriskie JB. Essential Clinical Immunology. 1st ed. Zabrieske JB, editor. Cambridge University Press; 2009. 372 p.
10. Roitt IM, Delves PJ. Roitt’s Essential Immunology, Tenth Edition [Internet]. 10th ed. Wiley-Blackwell; 2001. 481 p.
11. Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken). 2012;64:640–7.
12. Boers M, Brooks P, Strand C V., et al. The OMERACT filter for Outcome Measures in Rheumatology. The Journal of rheumatology. 1998;25(2):198–9. 13. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid
arthritis. J Am Med Assoc. 1949;140(8):659–62.
14. Pinto HG, Mangorrinha J. O desenho das termas : história da arquitectura termal portuguesa. 1st ed. Ministério da Economia e da Inovação: Direcção Geral de Energia e Geologia,; 2009. 513 p.
15. Gutenbrunner C, Bender T, Cantista P, et al. A proposal for a worldwide definition of health resort medicine, balneology, medical hydrology and climatology. Int J Biometeorol. 2010;54(5):495–507.
16. HydroGlobe - Definition of a global framework for hydrotherapy [Internet]. 2014. 17. Cantista P, Barroso H, Vaz R, et al. Le thermalisme au Portugal. Press therm
Clim. 2010;147(2):147–72.
18. Calado C. Carta de Nascentes Minerais: Notícia Explicativa. Atlas do Ambiente. Lisboa: Direcção-Geral do Ambiente; 1995. 37 p.
19. Jarvis JN, Frank MB. Functional genomics and rheumatoid arthritis: where have we been and where should we go? Genome Med. 2010;2(7):44.
20. Carbajo J, Maraver F. Hydrogen Sulfide and health. New insights. An Hidrol Médica. 2015;(10):93–105.
21. Clark RA. Misbehaving macrophages in the pathogenesis of psoriasis. J Clin Invest. 2006;116(8):2084–7.
22. Carrasco R, Barton A. Biomarkers of outcome in rheumatoid arthritis. Rheumatol Reports. 2010;2(1):3.
23. Stucki G, Cieza A. The International Classification of Functioning, Disability and Health (ICF) Core Sets for rheumatoid arthritis: a way to specify functioning. Ann Rheum Dis. 2004;63 Suppl 2:ii40–5.
24. Chen H, Shoumura S, Emura S, et al. Tibetan Medicated-Bath Therapy may Improve Adjuvant Arthritis in Rat. Evid Based Complement Alternat Med. 2009;6(2):211–7.
25. Zhao SL, Geng PL, Sang J. Immune function of rheumatoid arthritis treated by medicated-bath therapy in Tibetan medicine. Zhongguo Zhong Xi Yi Jie He Za Zhi. 1993;13(8):467–70, 452–3.
26. Woods JM, Katschke KJ, Tokuhira M, et al. Reduction of inflammatory cytokines and prostaglandin E2 by IL-13 gene therapy in rheumatoid arthritis synovium. J Immunol. 2000;165(5):2755–63.
27. Brosseau L, Robinson V, Léonard G, et al. Efficacy Of Balneotherapy For
Rheumatoid Arthritis: A Meta-analysis. Phys Ther Rev. Maney; 2002;7(2):67–87. 28. Verhagen AP, Bierma-Zeinstra SMA, Cardoso JR, et al. Balneotherapy for
rheumatoid arthritis. Cochrane database Syst Rev. 2004;(4):Assessed as up.to.date in 2007.
29. Falagas ME, Zarkadoulia E, Rafailidis PI. The therapeutic effect of
balneotherapy: evaluation of the evidence from randomised controlled trials. Int J Clin Pract. 2009;63(7):1068–84.
30. Fioravanti A, Cantarini L, Guidelli GM, et al. Mechanisms of action of spa therapies in rheumatic diseases: what scientific evidence is there? Rheumatol Int. 2011;31(1):1–8.
31. Firestein GS, Budd RC, Harris ED, et al. Kelley’s Textbook of Rheumatology. 8th ed. Elsevier Science Health Science Division, 2008; 2008. 2064 p. 32. van Tubergen A. A brief history of spa therapy. Ann Rheum Dis.
2002;61(3):273–5.
33. Boutron I, Moher D, Tugwell P, et al. A checklist to evaluate a report of a
nonpharmacological trial (CLEAR NPT) was developed using consensus. J Clin Epidemiol. 2005;58(12):1233–40.
34. Katz U, Shoenfeld Y, Zakin V, et al. Scientific evidence of the therapeutic effects of dead sea treatments: a systematic review. Semin Arthritis Rheum.
2012;42(2):186–200.
35. Nasermoaddeli A, Kagamimori S. Balneotherapy in medicine: A review. Environ Health Prev Med. 2005;10(4):171–9.
36. Sukenik S, Buskila D, Neumann L, et al. Sulphur bath and mud pack treatment for rheumatoid arthritis at the Dead Sea area. Ann Rheum Dis. 1990;49(2):99– 102.
37. Sukenik S, Neumann L, Buskila D, et al. Dead Sea bath salts for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 1990;8(4):353–7.
38. Elkayam O, Wigler I, Tishler M, et al. Effect of spa therapy in Tiberias on patients with rheumatoid arthritis and osteoarthritis. J Rheumatol.
1991;18(12):1799–803.
39. Sukenik S, Neumann L, Flusser D, et al. Balneotherapy for rheumatoid arthritis at the Dead Sea. Isr J Med Sci. 1995;31(4):210–4.
40. Yurtkuran M, Dilek K, Güllülü M, et al. A randomized, controlled study of balneotherapy in patients with rheumatoid arthritis. Phys Medizin, Rehabil Kurortmedizin. 1999;09(03):92–6.
41. Franke A, Reiner L, Pratzel HG, et al. Long-term efficacy of radon spa therapy in rheumatoid arthritis--a randomized, sham-controlled study and follow-up.
Rheumatology. 2000;39(8):894–902.
42. Franke A, Reiner L, Resch K-L. Long-term benefit of radon spa therapy in the rehabilitation of rheumatoid arthritis: a randomised, double-blinded trial. Rheumatol Int. 2007;27(8):703–13.
43. Franke A, Franke T. Long-term benefits of radon spa therapy in rheumatic diseases: results of the randomised, multi-centre IMuRa trial. Rheumatol Int. 2013;33(11):2839–50.
44. Zdrojewicz Z, Strzelczyk JJ. Radon treatment controversy. Dose Response. 2006;4(2):106–18.
45. Frontera WR, editor. DeLisa’s Physical Medicine and Rehabilitation: Principles and Practice [Internet]. 5th ed. Lippincott Williams & Wilkins; 2010. 2432 p. 46. Vliet Vlieland TPM, Li LC. Rehabilitation in rheumatoid arthritis and ankylosing
spondylitis: differences and similarities. Clin Exp Rheumatol. 2009;27(4 Suppl 55):S171–8.
47. Nguyen M, Revel M, Dougados M. Prolonged effects of 3 week therapy in a spa resort on lumbar spine, knee and hip osteoarthritis: follow-up after 6 months. A randomized controlled trial. Br J Rheumatol. 1997;36(1):77–81.
48. Bender T, Balint P V, Balint GP. A brief history of spa therapy. Ann Rheum Dis. 2002;61(10):949; author reply 949–50.
49. Sukenik S, Abu-Shakra M, Flusser D. Balneotherapy in autoimmune disease. Isr J Med Sci. 1997;33(4):258–61.
50. Marković M, Majkić-Singh N, Ignjatović S. Beneficial effects of cellular stress response in traditional spa treatment of rheumatoid arthritis. Clin Lab.
2009;55(5-6):235–41.
51. Santé HA De. Polyarthrite rhumatoïde : aspects thérapeutiques hors médicaments et chirurgie - aspects médico-sociaux et organisationnels [Internet]. Haute Autorité de Santé; 2007. 42 p.
52. Forestier R, André-Vert J, Guillez P, et al. Non-drug treatment (excluding surgery) in rheumatoid arthritis: clinical practice guidelines. Jt bone spine. 2009;76(6):691–8.
53. Agency for Healthcare Research and Quality Publication. Methods Guide for Effectiveness and Comparative Effectiveness Reviews [Internet]. AHRQ; 2013. 250 p.
54. Hall J, Skevington SM, Maddison PJ, et al. A randomized and controlled trial of hydrotherapy in rheumatoid arthritis. Arthritis Care Res. 1996;9(3):206–15. 55. Boutron I, Moher D, Altman DG, et al. Extending the CONSORT statement to
randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med. American College of Physicians; 2008;148(4):295–309.
56. Boutron I, Moher D, Altman DG, et al. Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic
treatments. Ann Intern Med. 2008;148(4):W60–6.
57. Boutron I, Dutton S, Ravaud P, et al. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA. 2010;303(20):2058–64.
58. Boutron I, Tubach F, Giraudeau B, et al. Methodological differences in clinical trials evaluating nonpharmacological and pharmacological treatments of hip and knee osteoarthritis. JAMA. 2003;290(8):1062–70.
59. Forestier R, Françon A, Graber-Duvernay B. Comment peut-on juger de la validité d’un essai thérapeutique ? Press therm Clim. 2005;142:75–99. 60. Ioannidis JPA, Evans SJW, Gøtzsche PC, et al. Better reporting of harms in
randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781–8.
61. Kwoh CK, Anderson LG, Greene JM, et al. Guidelines for the management of rheumatoid arthritis: 2002 update - American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Arthritis Rheum. 2002;46(2):328–46.
62. Karagülle Z, Karagülle M. Balneotherapy and spa therapy of rheumatic diseases in Turkey: a systematic review. Forsch Komplementarmed Klass Naturheilkd. 2004;11(1):33–41.
63. Chalmers I. The Cochrane collaboration: preparing, maintaining, and
disseminating systematic reviews of the effects of health care. Ann N Y Acad Sci. 1993;703:156–63; discussion 163–5.
64. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2007;66(1):34–45.
65. Forestier R, André-Vert J, Guillez P, et al. Polyarthrite rhumatoïde, aspects thérapeutiques hors médicament et chirurgie : aspects médico-sociaux et organisationnelsRecommandations de la Haute Autorité de santé.
Kinésithérapie, la Rev. 2012;12(123):30–40.
66. AFRETH. Recommandations en vue de l’évaluation des cures thermales. Press therm Clim. 2007;144:7–37.
Ther. 2004;84(10):934–72.
68. Rintala P, Kettunen H, McCubbin JA. Effects of a water exercise program for individuals with rheumatoid arthritis. Sport Med Train Rehabil. 1996;7(1):31–8. 69. Anandarajah AP, Schwarz EM. Dynamic exercises in patients with rheumatoid
arthritis. Ann Rheum Dis. 2004;63(11):1359–61.
70. van den Ende ECHM, Breedveld FC, le Cessie S, et al. Effect of intensive exercise on patients with active rheumatoid arthritis: a randomised clinical trial. Ann Rheum Dis. 2000;59(8):615–21.
71. Gossec L, Pavy S, Pham T, et al. Nonpharmacological treatments in early rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion. Joint Bone Spine. 2006;73(4):396–402.
72. Steinbrocker O. Therapeutic Criteria in Rheumatoid Arthritis. JAMA J Am Med Assoc. American Medical Association; 1949;140(8):659.
73. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: dimensions and practical applications. Health Qual Life Outcomes. 2003;1(1):20.
74. Huitema B. The Analysis of Covariance and Alternatives: Statistical Methods for Experiments, Quasi-Experiments, and Single-Case Studies [Internet]. John Wiley & Sons; 2011. 480 p.
75. Hayes AF. Introduction to Mediation, Moderation, and Conditional Process Analysis : A Regression-Based Approach. The Guilford Press; 2013. 507 p. 76. Boutron I, Guittet L, Estellat C, et al. Reporting methods of blinding in
randomized trials assessing nonpharmacological treatments. PLoS Med. 2007;4(2):e61.
77. Boutron I, Tubach F, Giraudeau B, et al. Blinding was judged more difficult to achieve and maintain in nonpharmacologic than pharmacologic trials. J Clin Epidemiol. 2004;57(6):543–50.
78. Carr AJ. Measuring quality of life: Is quality of life determined by expectations or experience? BMJ. 2001;322(7296):1240–3.
79. Carr AJ. Measuring quality of life: Are quality of life measures patient centred? BMJ. 2001;322(7298):1357–60.
80. Hewlett S, Ambler N, Almeida C, et al. Self-management of fatigue in
rheumatoid arthritis: a randomised controlled trial of group cognitive-behavioural therapy. Ann Rheum Dis. 2011;70(6):1060–7.
81. Wells GA, Becker J-C, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythr. Ann Rheum Dis. 2009;68(6):954–60.
82. Colebatch AN, Edwards CJ, Østergaard M, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72(6):804–14.
83. Dougados M, Devauchelle-Pensec V, Ferlet JF, et al. The ability of synovitis to predict structural damage in rheumatoid arthritis: a comparative study between clinical examination and ultrasound. Ann Rheum Dis. 2012;
recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–7.
85. Biswas S, Manikandan J, Pushparaj PN. Decoding the differential biomarkers of Rheumatoid arthritis and Osteoarthritis: A functional genomics paradigm to design disease specific therapeutics. Bioinformation. 2011;6(4):153–7.
86. Carrasco R, Barton A. Biomarkers of outcome in rheumatoid arthritis. Rheumatol Reports. 2010;2(1).
87. Rahmani M, Chegini H, Najafizadeh SR, et al. Detection of bone erosion in early rheumatoid arthritis: Ultrasonography and conventional radiography versus non- contrast magnetic resonance imaging. Clin Rheumatol. 2010;29(8):883–91. 88. Hau M, Schultz H, Tony HP, et al. Evaluation of pannus and vascularization of
the metacarpophalangeal and proximal interphalangeal joints in rheumatoid arthritis by high-resolution ultrasound (multidimensional linear array). Arthritis Rheum. 1999;42(11):2303–8.
89. Scutellari PN, Orzincolo C. Rheumatoid arthritis: sequences. Eur J Radiol. 1998;27 Suppl 1:S31–8.
90. Rowbotham EL, Grainger AJ. Rheumatoid arthritis: ultrasound versus MRI. AJR Am J Roentgenol. American Roentgen Ray Society; 2011;197(3):541–6. 91. Grassi W, Filippucci E. Ultrasonography and the rheumatologist. Curr Opin
Rheumatol. 2007;19(1):55–60.
92. Backhaus M, Kamradt T, Sandrock D, et al. Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum. 1999;42(6):1232–45.
93. Backhaus M. Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis. 2001;60(7):641–9.
94. Moreland LW, editor. Rheumatoid Arthritis (State of the Art). 2nd Ed. Remedica Pub Ltd; 2008.
95. Kuyken W, The Whoqol Group. The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization. Soc Sci Med. 1995;41(10):1403–9.
96. Miranda LC, Costa L, Ribeiro JS. NEAR study: Needs and Expectations in Rheumatoid ARthritis - do we know our patients needs? Acta Reum Port. 2010;35(3):314–23.
97. Whalley D, McKenna SP, de Jong Z, et al. Quality of life in rheumatoid arthritis. Br J Rheumatol. 1997;36(8):884–8.
98. Russell AS. Quality-of-life assessment in rheumatoid arthritis. Pharmacoeconomics. 2008;26(10):831–46.
99. Tugwell P, Idzerda L, Wells GA. Generic quality-of-life assessment in rheumatoid arthritis. Am J Manag Care. 2008;13 Suppl 9(4):831–46.
100. The Whoqol Group. The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties. Soc Sci Med. 1998;46(12):1569–85.
101. Leonardi M, Bickenbach J, Ustun TB, et al. The definition of disability: what is in a name? Lancet (London, England). 2006;368(9543):1219–21.
102. Bruce B, Fries JF. The Health Assessment Questionnaire (HAQ). Clin Exp Rheumatol. 2005;23(5 Suppl 39):S14–8.
103. Flurey CA, Morris M, Richards P, et al. It’s like a juggling act: rheumatoid arthritis patient perspectives on daily life and flare while on current treatment regimes. Rheumatology (Oxford). 2014;53(4):696–703.
104. Flurey CA, Hewlett S, Rodham K, et al. Men, rheumatoid arthritis, psychosocial impact and self-management: A narrative review. J Health Psychol. 2015; 105. Ryan S. Psychological effects of living with rheumatoid arthritis. Nurs Stand.
2014;29(13):52–9.
106. Gettings L. Psychological well-being in rheumatoid arthritis: a review of the literature. Musculoskeletal Care. 2010;8(2):99–106.
107. Dures E, Almeida C, Caesley J, et al. Patient preferences for psychological support in inflammatory arthritis: a multicentre survey. Ann Rheum Dis. 2014; 108. Schneider M, Manabile E, Tikly M. Social aspects of living with rheumatoid
arthritis: a qualitative descriptive study in Soweto, South Africa - a low resource context. Health Qual Life Outcomes. 2008;6:54.
109. EpiReuma. Estudo Epidemiológico das doenças reumáticas em Portugal Http://www.reumacensus.org/pdf/quadriptico_resultados_epireumapt.pdf [Internet].
Concedei-me, Senhor a:
Serenidade necessária para aceitar as coisas que não posso modificar, Coragem para modificar aquelas que posso e